Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
In: Annals of Oncology, Jg. 29 (2018-10-01), S. viii703
Online
unknown
Zugriff:
Titel: |
Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
|
---|---|
Autor/in / Beteiligte Person: | Kreipe, H.H. ; Forstbauer, Helmut ; Staib, Peter ; Christgen, Matthias ; Warm, M. ; Hackmann, John ; Liedtke, Cornelia ; Uleer, Christoph ; Wuerstlein, Rachel ; Gluz, O ; Harbeck, Nadia ; Grischke, EM ; Braun, Michael ; Nitz, U. ; Kümmel, S ; Aktas, Bahriye ; Kates, Ronald E. ; Schumacher, Claudia ; Potenberg, Jochem ; Lindner, Christoph |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 29 (2018-10-01), S. viii703 |
Veröffentlichung: | Elsevier BV, 2018 |
Medientyp: | unknown |
ISSN: | 0923-7534 (print) |
DOI: | 10.1093/annonc/mdy424.002 |
Schlagwort: |
|
Sonstiges: |
|